Renal hypoperfusion occurs as a result of reduced cardiac output, resulting in the activation of the renin–angiotensin–aldosterone system, which compensates for the hypoperfusion. However ...

Inhibitors of the renin–angiotensin–aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF). However, RAAS ...

The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well-treated, ...

In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, ...

Diabetic kidney disease (DKD), a common cause of end-stage renal disease ... dual specificity protein phosphatase1; RAAS, renin-angiotensin-aldosterone system; Tnpo1, transportin 1. 4.4 Glomerular ...

Aldosterone is known to bind to these receptors in the kidney and cardiovascular system, increasing blood pressure through increasing sodium reabsorption and probably other mechanisms. The drug is ...

A new blood pressure medication called lorundrostat has shown promising results in reducing blood pressure among patients ...

chronic kidney disease (CKD), the metabolic syndrome, and diabetes mellitus (Schrier, R. W. et al. Clin. J. Am. Soc. Nephrol. in press). The finding that angiotensin II and aldosterone are ...

Correspondence to: Dr John Main Renal Unit, James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK; john.mainstees.nhs.uk Atherosclerotic renal artery stenosis (ARAS) has become ...